Haloperidol Dosage for Cannabis Hyperemesis Syndrome
For acute cannabis hyperemesis syndrome in adults presenting to the emergency department, administer haloperidol 5 mg intramuscularly as the initial dose, which can provide rapid symptom relief. 1, 2
Acute Management Approach
The 2024 AGA Clinical Practice Update identifies haloperidol as one of the supported treatments for acute CHS management, though evidence is limited to case series and small clinical trials 1. The most commonly cited effective dose in clinical practice is:
- 5 mg intramuscularly for acute vomiting episodes 2
This dopamine antagonist approach has shown clinical benefit in the limited available studies 3. The mechanism likely involves blocking dopamine receptors in the chemoreceptor trigger zone and vomiting center, which helps counteract the paradoxical hyperemesis caused by chronic cannabis use.
Oral Dosing Considerations
If transitioning to oral therapy or for less severe presentations, the FDA-approved haloperidol dosing guidelines suggest 4:
- Initial oral dosing: 0.5-2 mg twice or three times daily for moderate symptomatology
- For severe symptomatology: 3-5 mg twice or three times daily
- Dosage can be adjusted upward as needed, with daily doses up to 100 mg used in some resistant cases
However, these FDA guidelines are for general antipsychotic use, not specifically for CHS. The acute IM dose of 5 mg appears most evidence-based for CHS specifically.
Important Clinical Caveats
Avoid opioids entirely - they worsen nausea and carry high addiction risk in this population 1, 5. This is a critical pitfall, as the severe abdominal pain may tempt providers to use opioids.
Alternative acute therapies supported by the same guideline include 1:
- Topical capsaicin 0.1% cream applied to abdomen
- Benzodiazepines (though these should not be first-line 5)
- Droperidol (another dopamine antagonist, similar mechanism to haloperidol)
- Promethazine, olanzapine, or ondansetron
Monitor for extrapyramidal side effects with haloperidol, particularly akathisia and dystonic reactions, which can occur even with single doses.
Definitive Treatment
The only curative treatment is sustained cannabis cessation 1, 2. Haloperidol is purely symptomatic management for acute episodes. Patients require counseling about permanent cannabis abstinence, as symptoms will recur with continued use. The diagnosis is only definitively confirmed by complete symptom resolution after 6-12 months of documented abstinence 2.
For long-term prophylaxis in patients working toward abstinence, tricyclic antidepressants (amitriptyline 75-100 mg at bedtime) are recommended 1, not haloperidol.